239 related articles for article (PubMed ID: 33437906)
1. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
2. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
[TBL] [Abstract][Full Text] [Related]
3. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
5. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma.
Jun TW; Yeh ML; Yang JD; Chen VL; Nguyen P; Giama NH; Huang CF; Hsing AW; Dai CY; Huang JF; Chuang WL; Roberts LR; Yu ML; Nguyen MH
Liver Int; 2018 May; 38(5):895-902. PubMed ID: 29045023
[TBL] [Abstract][Full Text] [Related]
6. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
9. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
Wang X; Wei S; Wei Y; Wang X; Xiao F; Feng Y; Zhu Q
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):889-898. PubMed ID: 37395242
[TBL] [Abstract][Full Text] [Related]
10. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
11. Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.
Tavakoli H; Robinson A; Liu B; Bhuket T; Younossi Z; Saab S; Ahmed A; Wong RJ
Dig Dis Sci; 2017 Aug; 62(8):2174-2181. PubMed ID: 28474143
[TBL] [Abstract][Full Text] [Related]
12. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.
van Meer S; van Erpecum KJ; Sprengers D; Coenraad MJ; Klümpen HJ; Jansen PL; IJzermans JN; Verheij J; van Nieuwkerk CM; Siersema PD; de Man RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):352-9. PubMed ID: 26629867
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
15. [Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis--retrospective study].
Witjes CD; de Man RA; Eskens FA; Dwarkasing RS; Zondervan PE; Verhoef C; Ijzermans JN
Ned Tijdschr Geneeskd; 2010; 154():A1747. PubMed ID: 20719013
[TBL] [Abstract][Full Text] [Related]
16. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience.
Chen VL; Yeh ML; Le AK; Jun M; Saeed WK; Yang JD; Huang CF; Lee HY; Tsai PC; Lee MH; Giama N; Kim NG; Nguyen PP; Dang H; Ali HA; Zhang N; Huang JF; Dai CY; Chuang WL; Roberts LR; Jun DW; Lim YS; Yu ML; Nguyen MH
Aliment Pharmacol Ther; 2018 Jul; 48(1):44-54. PubMed ID: 29797518
[TBL] [Abstract][Full Text] [Related]
17. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
18. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
[TBL] [Abstract][Full Text] [Related]
19. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.
Castelló B; Aguilera V; Blázquez MT; Rubín Á; García M; Vinaixa C; Benlloch S; SanJuan F; Montalva E; López R; Berenguer M
Ann Hepatol; 2019; 18(6):855-861. PubMed ID: 31543468
[TBL] [Abstract][Full Text] [Related]
20. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]